Drug Profile

long-acting amylin analog - Abbvie/Gubra

Alternative Names: GUB-014295; GUBamy

Latest Information Update: 19 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gubra
Developer AbbVie; Gubra
Class Obesity therapies; Peptide hormones
Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Obesity

Most Recent Events

19 Mar 2025 Gubra files clinical trial application for long acting amylin analog with UK's MHRA in Obesity before March 2025
19 Mar 2025 UK's MHRA approves clinical trial application for long acting amylin analog in Obesity before March 2025
17 Mar 2025 Pharmacokinetics and pharmacodynamics data from a preclinical study in Obesity released by Gubra

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com